Progression of subclinical atherosclerosis in subjects with rheumatoid arthritis and the metabolic syndrome

Atherosclerosis. 2018 Apr:271:84-91. doi: 10.1016/j.atherosclerosis.2018.02.019. Epub 2018 Feb 17.

Abstract

Background and aims: Rheumatoid arthritis (RA) has been associated with an increased risk of atherosclerosis. We aimed to evaluate the progression of carotid intima media thickness (cIMT) in RA patients subject to a cardiovascular treat-to-target intervention. In addition, the presence of the metabolic syndrome (MetS) on cIMT outcomes was evaluated.

Methods: We performed a cohort analysis of FRANCIS, in which RA patients ≤70 years without CVD or diabetes mellitus were randomized for either a treat-to-target intervention or usual care concerning CVD risk factors. MetS was scored at baseline.

Results: Three-year data was available in 212 well-controlled RA patients. The treat-to-target intervention resulted in a lower cIMT progression over three years compared to the usual care. However, there was no difference in cIMT at three years between groups. MetS was present in 40.1% of RA patients. Baseline cIMT was significantly higher in RA patients with MetS compared to those without (0.619 (0.112) versus 0.557 (0.104) mm; p < 0.001). After three years, cIMT progression was comparable (0.043 (0.071) versus 0.043 (0.072) mm; p = 0.96). In RA patients with MetS, the presence of plaques increased over three years from 12.9% to 23.5% (p = 0.01). The type of intervention had no effect on cIMT progression in RA patients with MetS. However, in subjects without MetS, treat-to-target resulted in a lower progression.

Conclusions: RA patients with MetS showed an increased CVD risk profile based on both a higher prevalence of CVD risk factors and structural vascular changes. A treat-to-target approach of CVD risk factors reduced cIMT progression only in RA patients without MetS.

Keywords: Atherosclerosis; Cardiovascular risk; Carotid artery; Intervention; Intima media thickness.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antihypertensive Agents / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / epidemiology*
  • Arthritis, Rheumatoid / mortality
  • Arthritis, Rheumatoid / therapy
  • Asymptomatic Diseases
  • Carotid Artery Diseases / diagnostic imaging
  • Carotid Artery Diseases / epidemiology*
  • Carotid Artery Diseases / mortality
  • Carotid Artery Diseases / prevention & control
  • Carotid Artery, Common* / diagnostic imaging
  • Carotid Intima-Media Thickness
  • Disease Progression
  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Hypolipidemic Agents / therapeutic use
  • Male
  • Metabolic Syndrome / diagnosis
  • Metabolic Syndrome / epidemiology*
  • Metabolic Syndrome / mortality
  • Metabolic Syndrome / therapy
  • Middle Aged
  • Netherlands / epidemiology
  • Plaque, Atherosclerotic
  • Prevalence
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Risk Reduction Behavior
  • Time Factors
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Antirheumatic Agents
  • Hypoglycemic Agents
  • Hypolipidemic Agents